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intention of the International Associa-
tion for the Study of Lung Cancer to
presume to “sanction” the authority of
these publications.
The central question raised in the
letter by Lopez-Encuentra et al. asks
whether it is ever appropriate to use
the “p” descriptor in association with
(a) a TNM classification or stage or (b)
a T, N, or M category, in cases in
which resection has not been per-
formed. They accurately quote Gen-
eral Rule 2, and in practice, a pTNM
classification or pStage is most com-
monly applied when describing the ex-
tent of disease after surgical resection
and pathologic examination e.g. pT3
N2 M0, pStage IIIA. Although in this
situation the “pT” category will have
been assigned on the basis of a high
level of certainty, C4, and it is usual to
afford the same level of certainty to
the “pN” category, the “M0” category
is always assumed on the basis of the
clinical classification, with a Certainty
factor of C1 or C2. Some would fur-
ther question whether it is appropriate
to assign a “pN” category after resec-
tion in cases in which the N3 nodes
have not been thoroughly evaluated or
in which the assessment of pN0 has
been based on a casual assessment of
the ipsilateral nodes in N1 and/or N2
locations. In this edition of TNM, we
have sought to address the latter by
reinstating a minimum number of
lymph nodes expected to assure pN0
and have suggested that an “R1(un)”
classification be trialed for cases,
which are designated pN0 on less ro-
bust evidence.
There are circumstances in
which surgical treatment is inappropri-
ate and yet a higher Certainty factor,
C3, has been achieved in the patho-
logic confirmation of the T, N, or M
category. Surgical procedures such a
mediastinoscopy have traditionally
been accorded a specificity of 100%.
We are fortunate that an expanding
armamentarium is now available in
thoracic oncology, which allows us to
assess nodal status by less invasive
procedures, such as endobronchial ul-
trasound and endoscopic ultrasound,
with a similarly high specificity. It is
therefore not illogical to assign a pN
category in such circumstances.
Although General Rules must re-
main inviolable, it is surely appropri-
ate that their interpretation evolves as
the science of oncology improves. In-
deed, in the TNM Supplement: A com-
mentary on Uniform Use,3 on page 97,
the Site specific Recommendations for
pT and pN in Lung and Pleural Tu-
mors requires only the “Microscopic
confirmation of metastasis” when as-
signing a pN category.
We accept that the N2 case illus-
trated in the Frequently Asked Ques-
tions in Chapter 121 will have a different
prognosis to one in which a pN2 cate-
gory is assigned after surgical resection,
usually in cases in which a cN0 or cN1
category had been assigned prior to tho-
racotomy. However, this could be re-
lated to the different treatments appro-
priate in these scenaria or the reduced
performance status that could weigh
against surgery in some situations. Al-
though the anatomic extent of disease,
as described by the TNM classification,
remains the single most important prog-
nostic factor, the surest way to ensure
homogeneity within any study popula-
tion is to collect data on as many prog-
nostic factors as possible.
We hope that this clarifies the
situation.
Peter Goldstraw, MB, FRCS
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As Chair of the Trial Steering
Committee for the mesothelioma and
radical surgery trial, I was pleased to
see the preliminary results of this
study published in the Journal of Tho-
racic Oncology,1 with the positive as-
pects of the trial emphasized in an
accompanying editorial by Dr. Rusch.2
However, one should note that the
original trial design required the ran-
domization of 50 cases in 1 year, and
not the 3 plus years that proved nec-
essary to achieve this accrual. Given
the high incidence of malignant pleu-
ral mesothelioma in the United King-
dom and the organizational advantages
in this county, emphasized in the edi-
torial, this does suggest that those who
expressed concern as to the feasibility
of this randomization, mentioned in
the Discussion, were not completely
wrong! I raise this issue, as it must
have a profound impact on the ques-
tion to be posed in any follow-up
study, an issue on which the authors of
the article, and the editorial seem to
hold differing opinions.
Peter Goldstraw, MB, FRCS
Department of Thoracic Surgery
Royal Brompton Hospital
London, United Kingdom
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